Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 26, 2013, Pages 10616-10621

  Sutto, Ludovico ^a   Gervasio, Francesco Luigi ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Conformational changes; Resistance causing mutations

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; METHIONINE; THREONINE;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; DRUG BINDING SITE; ENZYME ACTIVE SITE; LANDSCAPE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTON TRANSPORT; SOMATIC MUTATION;

CONFORMATIONAL CHANGES; RESISTANCE-CAUSING MUTATIONS;

AMINO ACID SUBSTITUTION; CATALYTIC DOMAIN; COMPUTER SIMULATION; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTATION; NEOPLASMS; ONCOGENES; PROTEIN CONFORMATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; THERMODYNAMICS;

PYRONIA TITHONUS;

EID: 84879510153     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1221953110     Document Type: Article

References (49)

1. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127-137.
2. Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458(7239): 719-724.
3. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216): 1061-1068.
4. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341-354.
5. Schreiber AB, Libermann TA, Lax I, Yarden Y, Schlessinger J (1983) Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal antireceptor antibodies. J Biol Chem 258(2):846-853.
6. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125(6): 1137-1149.
7. Arkhipov A, et al. (2013) Architecture and membrane interactions of the EGF receptor. Cell 152(3):557-569.
8. Endres NF, et al. (2013) Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152(3):543-556.
9. Jeffrey PD, et al. (1995) Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376(6538):313-320.
10. Noble MEM, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303(5665):1800-1805.
11. Wood ER, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64(18):6652-6659.
12. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118(2):257-262.
13. Forbes SA, et al. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39(Database issue):D945-D950.
14. Hashimoto K, Rogozin IB, Panchenko AR (2012) Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases. Hum Mutat 33(11):1566-1575.
15. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139.
16. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306-13311.
17. Kobayashi S, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786-792.
18. Yun CH, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3):217-227.
19. Shan Y, et al. (2012) Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 149(4):860-870.
20. Paez JG, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500.
21. Yun CH, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105(6):2070-2075.
22. Wan S, Wright DW, Coveney PV (2012) Mechanism of drug efficacy within the EGF receptor revealed by microsecond molecular dynamics simulation. Mol Cancer Ther 11(11):2394-2400.
23. Park JH, Liu Y, Lemmon MA, Radhakrishnan R (2012) Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J 448(3):417-423.
24. Pao W, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73.
25. Tam IYS, et al. (2009) Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 8(8):2142-2151.
26. Lindorff-Larsen K, et al. (2012) Systematic validation of protein force fields against experimental data. PLoS ONE 7(2):e32131.
27. Shaw DE, et al. (2009) Millisecond-scale molecular dynamics simulations on Anton (ACM Press, New York), pp 1-11.
28. Bussi G, Gervasio FL, Laio A, Parrinello M (2006) Free-energy landscape for beta hairpin folding from combined parallel tempering and metadynamics. J Am Chem Soc 128(41):13435-13441.
29. Sutto L, Marsili S, Gervasio FL (2012) New advances in metadynamics. WIREs Comput Mol Sci 2:771-779.
30. Laio A, Parrinello M (2002) Escaping free-energy minima. Proc Natl Acad Sci USA 99(20):12562-12566.
31. Bonomi M, Parrinello M (2010) Enhanced sampling in the well-tempered ensemble. Phys Rev Lett 104(19):190601-190604.
32. Berteotti A, et al. (2009) Protein conformational transitions: the closure mechanism of a kinase explored by atomistic simulations. J Am Chem Soc 131(1):244-250.
33. Lovera S, et al. (2012) The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J Am Chem Soc 134(5):2496-2499.
34. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC (1999) Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3(5):629-638.
35. De Bondt HL, et al. (1993) Crystal structure of cyclin-dependent kinase 2. Nature 363(6430):595-602.
36. Shan Y, Arkhipov A, Kim ET, Pan AC, Shaw DE (2013) Transitions to catalytically inactive conformations in EGFR kinase. Proc Natl Acad Sci USA 110(18):7270-7275.
37. Whitford PC, Miyashita O, Levy Y, Onuchic JN (2007) Conformational transitions of adenylate kinase: switching by cracking. J Mol Biol 366(5):1661-1671.
38. Kornev AP, Haste NM, Taylor SS, Eyck LF (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 103(47):17783-17788.
39. Shan Y, et al. (2009) A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci USA 106(1):139-144.
40. Jura N, et al. (2011) Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 42(1):9-22.
41. Dixit A, Verkhivker GM (2011) Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. PLOS Comput Biol 7(10):e1002179.
42. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234(3):779-815.
43. Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. J Chem Theory Comput 4:435-447.
44. Bonomi M, et al. (2009) PLUMED: a portable plugin for free-energy calculations with molecular dynamics. Comput Phys Commun 180:1961-1972.
45. Lindorff-Larsen K, et al. (2010) Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78(8):1950-1958.
46. Best RB, Hummer G (2009) Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides. J Phys Chem B 113(26):9004-9015.
47. Mahoney MW, Jorgensen WL (2000) A five-site model for liquid water and the reproduction of the density anomaly by rigid, nonpolarizable potential functions. J Chem Phys 112:8910.
48. Essmann U, et al. (1995) A smooth particle mesh Ewald method. J Chem Phys 103: 8577.
49. Bussi G, Donadio D, Parrinello M (2007) Canonical sampling through velocity rescaling. J Chem Phys 126(1):014101.